Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:TPTX

Turning Point Therapeutics (TPTX) Stock Price, News & Analysis

Turning Point Therapeutics logo

About Turning Point Therapeutics Stock (NASDAQ:TPTX)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$76.01
$76.01
50-Day Range
$74.80
$76.01
52-Week Range
$23.77
$82.20
Volume
4,322 shs
Average Volume
1.14 million shs
Market Capitalization
$3.81 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California.

Remove Ads
Receive TPTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Turning Point Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TPTX Stock News Headlines

Turning Point of Tampa Now In-Network with Blue Cross Blue Shield Insurance
Alert: DOGE goes live
Elon will most likely be at the helm of it all. And just days from now, could bring about the biggest economic transformation in American history. See, there's one particular part of Elon and Trump's plans that you need to pay special attention to right now.
Turning Point Brands Inc.
Alzheimer’s: A Turning Point?
Turning Point Brands Inc (TPB)
See More Headlines

TPTX Stock Analysis - Frequently Asked Questions

Turning Point Therapeutics, Inc. (NASDAQ:TPTX) announced its quarterly earnings results on Tuesday, November, 9th. The company reported ($1.34) earnings per share for the quarter, missing the consensus estimate of ($1.26) by $0.08. The company earned $0.46 million during the quarter.

Turning Point Therapeutics (TPTX) raised $167 million in an initial public offering (IPO) on Wednesday, April 17th 2019. The company issued 9,300,000 shares at a price of $18.00 per share. Goldman Sachs, SVB Leerink and Wells Fargo Securities acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Turning Point Therapeutics investors own include Meta Platforms (META), Diamondback Energy (FANG), Gilead Sciences (GILD), HubSpot (HUBS), Netflix (NFLX), NVIDIA (NVDA) and Pfizer (PFE).

Company Calendar

Last Earnings
11/09/2021
Today
3/15/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TPTX
Fax
N/A
Employees
250
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-236,550,000.00
Pretax Margin
-33,959.03%

Debt

Sales & Book Value

Annual Sales
$30.83 million
Price / Cash Flow
N/A
Book Value
$15.84 per share
Price / Book
4.80

Miscellaneous

Free Float
45,768,000
Market Cap
$3.81 billion
Optionable
Not Optionable
Beta
-0.18
7 Top Nuclear Stocks To Buy Now Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:TPTX) was last updated on 3/15/2025 by MarketBeat.com Staff
From Our Partners